---
title: "PD-L1 PET/CT with 89Zr-atezolizumab to assess tumour saturation during atezolizumab therapy"
id: "british-journal-of-cancer-0-programmed-death-ligand-1-pd-l1-pet-ct-imaging-to-evaluate-tumour-saturation"
canonical_url: "https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-programmed-death-ligand-1-pd-l1-pet-ct-imaging-to-evaluate-tumour-saturation"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "British Journal of Cancer"
source_url: "https://www.nature.com/articles/s41416-026-03595-8"
published_at: "2026-09-10T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# PD-L1 PET/CT with 89Zr-atezolizumab to assess tumour saturation during atezolizumab therapy
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-programmed-death-ligand-1-pd-l1-pet-ct-imaging-to-evaluate-tumour-saturation
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** British Journal of Cancer
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41416-026-03595-8)
- **Published At:** 2026-09-10T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- This open-label imaging study evaluated tumour target saturation by the PD-L1 antibody **atezolizumab** using immunoPET with **89Zr-atezolizumab** in patients with advanced solid tumours. - Patients received therapeutic 1200 mg atezolizumab IV, then ~10 mg (37 MBq) 89Zr-atezolizumab after the therapeutic dose, with PET/CT imaging on days 4 and 7 after tracer injection. - Two cohorts: tracer after first therapeutic dose (cohort 1) or after both first and second doses (cohort 2); biopsies were obtained around day 7 of each cycle for autoradiography and PD-L1 immunohistochemistry. - Primary imaging metrics included tumour SUVmax, normal tissue SUVmean, and tumour-to-background ratio (SUVmax/SUVmean background) using VOI-based analysis on reconstructed PET/CT scans. - On-treatment geometric mean tumour SUVmax at day 7 was similar between cycle 1 (5.5, 95% CI 4.4–6.9) and cycle 2 (5.4, 95% CI 4.3–6.8; N = 13; P = 0.88). - Geometric mean tumour-to-background ratio was 1.67 (95% CI 1.15–2.41) in cycle 1 and 1.53 (N = 11, 95% CI 1.05–2.21) in cycle 2 (P = 0.32). - Higher tumour-to-background ratios showed a positive trend with best overall response (p trend 0.069). - Autoradiography detected signal in tumour biopsies obtained on-treatment. Compared with previously reported pre-treatment 89Zr-atezolizumab data, on-treatment uptake in lesions and spleen was lower, while blood pool SUVmean was higher, suggesting **partial PD-L1 tumour saturation** during therapeutic atezolizumab dosing. - ClinicalTrials.gov identifiers for the companion trials are NCT02453984 and NCT02478099. Detailed methods and statistical analysis were reported in Supplementary Data. - The study was approved by the Medical Ethical Committee of UMCG, patients provided informed consent, and adverse events were scored per NCI CTCAE v4.03.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41416-026-03595-8#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![British Journal of Cancer](https://media.springernature.com/full/nature-cms/uploads/product/bjc/header-76ac17391903a21e28f15ff5df31f5fa.svg) ](https://www.nature.com/bjc) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41416-026-03595-8) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/bjc/research-articles) * [ Reviews & Analysis ](https://www.nature.com/bjc/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/bjc/news-and-comment) * [ Current issue ](https://www.nature.com/bjc/current-issue) * [ Collections ](https://www.nature.com/bjc/collections) * [Follow us on X ](https://twitter.com/BrJCancer) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41416) * [ RSS feed ](https://www.nature.com/bjc.rss) * [ About the journal ](javascript:;) ## About the journal * [ Journal Information ](https://www.nature.com/bjc/journal-information) * [ Open access publishing ](https://www.nature.com/bjc/open-access) * [ About the Editors ](https://www.nature.com/bjc/editors) * [ Contact ](https://www.nature.com/bjc/contact) * [ Special Issues ](https://www.nature.com/bjc/special-issues) * [ For Advertisers ](https://www.nature.com/bjc/advertising) * [ Subscribe ](https://www.nature.com/bjc/subscribe) * [ Publish with us ](javascript:;) ## Publish with us * [ For Authors & Referees ](https://www.nature.com/bjc/authors-and-referees) * [ Language editing services ](https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022) * [Open access funding](https://www.nature.com/bjc/open-access-funding) * [Submit manuscript ](https://mts-bjcancer.nature.com/) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41416) * [ RSS feed ](https://www.nature.com/bjc.rss) 1. [nature](https://www.nature.com/) 2. [british journal of cancer](https://www.nature.com/bjc) 3. [articles](https://www.nature.com/bjc/articles?type=article) 4. article Programmed death ligand 1 (PD-L1) PET/CT imaging to evaluate tumour saturation during atezolizumab treatment [ Download PDF ](https://www.nature.com/articles/s41416-026-03595-8.pdf) [ Download PDF ](https://www.nature.com/articles/s41416-026-03595-8.pdf) * Article * [Open access](https://www.springernature.com/gp/open-science/about/the-fundamentals-of-open-access-and-open-research) * Published: 10 September 2026 Clinical Study # Programmed death ligand 1 (PD-L1) PET/CT imaging to evaluate tumour saturation during atezolizumab treatment * [Jahlisa S. Hooiveld-Noeken](https://www.nature.com/articles/s41416-026-03595-8#auth-Jahlisa_S_-Hooiveld_Noeken-Aff1)[1](https://www.nature.com/articles/s41416-026-03595-8#Aff1), * [Pim P. van de Donk](https://www.nature.com/articles/s41416-026-03595-8#auth-Pim_P_-Donk-Aff1)[1](https://www.nature.com/articles/s41416-026-03595-8#Aff1), * [Laura Kist de Ruijter](https://www.nature.com/articles/s41416-026-03595-8#auth-Laura-Kist_de_Ruijter-Aff1)[1](https://www.nature.com/articles/s41416-026-03595-8#Aff1), * [Iris C. Kok](https://www.nature.com/articles/s41416-026-03595-8#auth-Iris_C_-Kok-Aff1)[1](https://www.nature.com/articles/s41416-026-03595-8#Aff1), * [Claudia A. J. van Winkel](https://www.nature.com/articles/s41416-026-03595-8#auth-Claudia_A__J_-Winkel-Aff1)[1](https://www.nature.com/articles/s41416-026-03595-8#Aff1), * [Danique Giesen](https://www.nature.com/articles/s41416-026-03595-8#auth-Danique-Giesen-Aff2)[2](https://www.nature.com/articles/s41416-026-03595-8#Aff2), * [Marjolijn N. Lub-de Hooge](https://www.nature.com/articles/s41416-026-03595-8#auth-Marjolijn_N_-Lub_de_Hooge-Aff3)[3](https://www.nature.com/articles/s41416-026-03595-8#Aff3), * [Adrienne H. Brouwers](https://www.nature.com/articles/s41416-026-03595-8#auth-Adrienne_H_-Brouwers-Aff2) [ORCID: orcid.org/0000-0003-2698-1516](https://orcid.org/0000-0003-2698-1516)[2](https://www.nature.com/articles/s41416-026-03595-8#Aff2), * [Sjoukje F. Oosting](https://www.nature.com/articles/s41416-026-03595-8#auth-Sjoukje_F_-Oosting-Aff1) [ORCID: orcid.org/0000-0003-2754-6997](https://orcid.org/0000-0003-2754-6997)[1](https://www.nature.com/articles/s41416-026-03595-8#Aff1), * [Frederike Bensch](https://www.nature.com/articles/s41416-026-03595-8#auth-Frederike-Bensch-Aff4)[4](https://www.nature.com/articles/s41416-026-03595-8#Aff4), * [Lotte M. Smit](https://www.nature.com/articles/s41416-026-03595-8#auth-Lotte_M_-Smit-Aff1) [ORCID: orcid.org/0000-0002-6010-8713](https://orcid.org/0000-0002-6010-8713)[1](https://www.nature.com/articles/s41416-026-03595-8#Aff1), * [Carolien P. Schröder](https://www.nature.com/articles/s41416-026-03595-8#auth-Carolien_P_-Schr_der-Aff1-Aff8)[1](https://www.nature.com/articles/s41416-026-03595-8#Aff1) [nAff8](https://www.nature.com/articles/s41416-026-03595-8#nAff8), * [Mathilde Jalving](https://www.nature.com/articles/s41416-026-03595-8#auth-Mathilde-Jalving-Aff1) [ORCID: orcid.org/0000-0002-9142-9050](https://orcid.org/0000-0002-9142-9050)[1](https://www.nature.com/articles/s41416-026-03595-8#Aff1), * [Sjoerd G. Elias](https://www.nature.com/articles/s41416-026-03595-8#auth-Sjoerd_G_-Elias-Aff5)[5](https://www.nature.com/articles/s41416-026-03595-8#Aff5), * [Jourik A. Gietema](https://www.nature.com/articles/s41416-026-03595-8#auth-Jourik_A_-Gietema-Aff1) [ORCID: orcid.org/0000-0003-0629-7354](https://orcid.org/0000-0003-0629-7354)[1](https://www.nature.com/articles/s41416-026-03595-8#Aff1), * [Regula J. Deurloo](https://www.nature.com/articles/s41416-026-03595-8#auth-Regula_J_-Deurloo-Aff6)[6](https://www.nature.com/articles/s41416-026-03595-8#Aff6), * [Simon P. Williams](https://www.nature.com/articles/s41416-026-03595-8#auth-Simon_P_-Williams-Aff7)[7](https://www.nature.com/articles/s41416-026-03595-8#Aff7), * [Alexander Ungewickell](https://www.nature.com/articles/s41416-026-03595-8#auth-Alexander-Ungewickell-Aff7)[7](https://www.nature.com/articles/s41416-026-03595-8#Aff7), * [Derk-Jan A. de Groot](https://www.nature.com/articles/s41416-026-03595-8#auth-Derk_Jan_A_-Groot-Aff1) [ORCID: orcid.org/0000-0002-8306-6835](https://orcid.org/0000-0002-8306-6835)[1](https://www.nature.com/articles/s41416-026-03595-8#Aff1) & * … * [Elisabeth G. E. de Vries](https://www.nature.com/articles/s41416-026-03595-8#auth-Elisabeth_G__E_-Vries-Aff1) [ORCID: orcid.org/0000-0002-8949-7425](https://orcid.org/0000-0002-8949-7425)[1](https://www.nature.com/articles/s41416-026-03595-8#Aff1) Show authors [_British Journal of Cancer_](https://www.nature.com/bjc) (2026) [Cite this article](https://www.nature.com/articles/s41416-026-03595-8#citeas) [ Save article ](https://www.nature.com/articles/s41416-026-03595-8/save-research?_csrf=AW6-FiYUczM3CTz7duopFw-eP57jil6W) [ View saved research ](https://www.nature.com/saved-research) ## Abstract ### Background Little is known regarding tumour target saturation by the programmed death-ligand (PD-L1) antibody atezolizumab. Therefore, tumour saturation by the PD-L1 antibody atezolizumab in patients with advanced solid tumours was assessed using 89Zr-atezolizumab PET imaging. ### Methods Patients received 10 mg 89Zr-atezolizumab after the initial 2 cycles of 1200 mg atezolizumab, followed by PET/CT scans. Tracer uptake was calculated as tumour standardized uptake value (SUV)max, normal tissues SUVmean, and tumour-to-background ratio SUVmax/SUVmax tumour. Tumour biopsies were obtained around day 7 of both cycles for autoradiography and PD-L1 immunohistochemistry. Findings were compared with previously reported pretreatment 89Zr-atezolizumab PET/CT data. ### Results Geometric mean tumour SUVmax day 7 was similar between cycle 1 (5.5, 95% CI, 4.4–6.9) and 2 (5.4, 95% CI, 4.3–6.8, _N_ = 13 _, P_ = 0.88). Geometric mean tumour-to-background ratio was 1.67 (95% CI, 1.15–2.41) and 1.53 (_N_ = 11, 95% CI, 1.05–2.21, _P_ = 0.32), respectively. Higher tumour-to-background ratios showed a positive trend with best overall response _p_ trend 0.069. Autoradiography signal was present in tumour biopsies. On-treatment uptake was lower in the lesions and spleen, with a higher blood pool SUVmean than pre-treatment. ### Conclusions Compared to earlier reported pre-treatment 89Zr-atezolizumab PET/CT results, 89Zr-atezolizumab tumour uptake during treatment is lower, suggesting partial PD-L1 tumour saturation during atezolizumab treatment. ### ClinicalTrials.gov NCT02453984, NCT02478099 ### Explore related subjects Discover the latest articles and news in related subjects. * [Cancer immunotherapy](https://www.nature.com/subjects/cancer-immunotherapy) * [Translational research](https://www.nature.com/subjects/translational-research) * [Whole body imaging](https://www.nature.com/subjects/whole-body-imaging) ## Introduction Treatment with programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors has become the standard of care for multiple tumour types. Durable responses and increased overall survival can be achieved with immune checkpoint inhibitors administered as monotherapy or combined with other anticancer therapies [[1](https://www.nature.com/articles/s41416-026-03595-8#ref-CR1 "Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223–49.")]. Most cytotoxic agents are evaluated for maximum tolerated dose and dose-limiting toxicities during anticancer drug development. The PD-L1 antibody atezolizumab, which has received marketing approval from the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of several tumour types [[2](https://www.nature.com/articles/s41416-026-03595-8#ref-CR2 "Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909–20."),[3](https://www.nature.com/articles/s41416-026-03595-8#ref-CR3 "Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383:1328–39."),[4](https://www.nature.com/articles/s41416-026-03595-8#ref-CR4 "Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220–9."),[5](https://www.nature.com/articles/s41416-026-03595-8#ref-CR5 "Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF\(V600\) mutation-positive melanoma \(IMspire150\): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395:1835–44."),[6](https://www.nature.com/articles/s41416-026-03595-8#ref-CR6 "Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.")], however, has no clear maximum tolerated dose. This antibody is often administered at 1200 mg intravenously (IV) every 3 weeks. This regimen provides a mean trough concentration (Cmin) at steady state above the 6 μg/ml target serum concentration in phase 1 and 2 trials. This target serum concentration is based on preclinical data, suggesting that 6 μg/ml is required to saturate tumour lesions. For atezolizumab, apart from serum pharmacokinetics, little is known about the degree of target saturation achieved in tumours and the degree to which current dosing regimens saturate PD-L1 binding sites in tumours. Mouse positron emission tomography (PET) experiments with radioactively labelled immune checkpoint inhibitors suggest complete tumour saturation, but these models have limitations when translating the findings to the clinic [[7](https://www.nature.com/articles/s41416-026-03595-8#ref-CR7 "Deng R, Bumbaca D, Pastuskovas CV, Boswell CA, West D, Cowan KJ, et al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. mAbs. 2016;8:593–603."),[8](https://www.nature.com/articles/s41416-026-03595-8#ref-CR8 "Krache A, Fontan C, Pestourie C, Bardiès M, Bouvet Y, Payoux P, et al. Preclinical pharmacokinetics and dosimetry of an 89Zr labelled anti-PDL1 in an orthotopic lung cancer murine model. Front Med. 2022;8:741855."),[9](https://www.nature.com/articles/s41416-026-03595-8#ref-CR9 "Bansal A, Pandey MK, Barham W, Liu X, Harrington SM, Lucien F, et al. Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model. Nucl Med Biol. 2021;100-101:4–11."),[10](https://www.nature.com/articles/s41416-026-03595-8#ref-CR10 "Truillet C, Oh HLJ, Yeo SP, Lee CY, Huynh LT, Wei J, et al. Imaging PD-L1 expression with immunoPET. Bioconjug Chem. 2017;29:96–103.")]. ImmunoPET/CT can improve insight into the available PD-L1 binding sites. Previously, PD-L1 PET/CT imaging with zirconium-89 (89Zr) labelled atezolizumab, administered before atezolizumab treatment, provided insight into whole-body 89Zr-atezolizumab uptake in tumour lesions and atezolizumab biodistribution [[11](https://www.nature.com/articles/s41416-026-03595-8#ref-CR11 "Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24:1852–8.")]. It is, however, unclear whether therapeutic atezolizumab dosing results in saturation of PD-L1 binding sites in tumours. Therefore, we aimed to assess tumour PD-L1 saturation using 89Zr-atezolizumab PET/CT scans during atezolizumab treatment. ## Materials and methods Detailed Materials and Methods, including statistical analysis, are available in Supplementary Data [1](https://www.nature.com/articles/s41416-026-03595-8#MOESM1). ### Patient population and study design Adult patients with advanced solid tumours likely to benefit from atezolizumab were eligible, with ECOG 0–2 and RECIST v1.1 measurable disease. Stable brain or leptomeningeal metastases were allowed; other criteria matched the pretreatment 89Zr-atezolizumab PET/CT study [[11](https://www.nature.com/articles/s41416-026-03595-8#ref-CR11 "Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24:1852–8.")]. This open-label imaging study was performed in combination with a companion atezolizumab treatment study at the University Medical Centre Groningen (UMCG), the Netherlands (ClinicalTrials.gov: NCT02453984, NCT02478099). Patients received a therapeutic dose of 1200 mg atezolizumab over 120 min IV, followed by 37 MBq (1 mCi) 89Zr-atezolizumab (~10 mg antibody) directly after the therapeutic dose. Atezolizumab treatment was given in 3 weekly cycles for up to 2 years. In cohort 1, 89Zr-atezolizumab was administered after the first therapeutic dose, followed by PET/CT imaging on days 4 and 7, and a tumour biopsy thereafter (Supplementary Fig. [1](https://www.nature.com/articles/s41416-026-03595-8#MOESM1)). In cohort 2, the tracer was administered after the first and second therapeutic atezolizumab doses, followed by PET/CT imaging and biopsy on the same schedule as in cohort 1 (Supplementary Fig. [1](https://www.nature.com/articles/s41416-026-03595-8#MOESM1)). Tumour response was assessed per (i)RECIST v1.1 every 6–9 weeks using diagnostic CT-scans [[12](https://www.nature.com/articles/s41416-026-03595-8#ref-CR12 "Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline \(version 1.1\). Eur J Cancer. 2009;45:228–47.")]. Progression-free survival (PFS) was defined as the time from treatment initiation to first confirmed progression or death, whichever occurred first. Adverse events (AEs) were scored according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 [[13](https://www.nature.com/articles/s41416-026-03595-8#ref-CR13 "National Cancer Institute. Common Terminology Criteria for Adverse Events \(CTCAE\) v4.0 \(NCI, 2009\).")]. This study was approved by the Medical Ethical Committee of the UMCG and the Central Committee on Research Involving Human Subjects and registered individually. All patients provided written informed consent. ### 89Zr-atezolizumab PET/CT 89Zr-atezolizumab tracer production at the UMCG and the scanning protocol were as described previously [[11](https://www.nature.com/articles/s41416-026-03595-8#ref-CR11 "Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24:1852–8.")], acquiring images on days 4 and 7 after tracer injection. All PET/CT scans were preceded by a low-dose CT scan with a Biograph mCT 40- or 64-slice PET/CT. Images were reconstructed using the EARL1 algorithm [[14](https://www.nature.com/articles/s41416-026-03595-8#ref-CR14 "Kaalep A, Huisman M, Sera T, Vugts D, Boellaard R, EARL; EATRIS; TRISTAN Consortium \(#IB4SD-116106\). Feasibility of PET/CT system performance harmonisation for quantitative multicentre 89Zr studies. EJNMMI Phys. 2018;5:26.")]. PET/CT images were analysed with the Accurate tool, applying a volume-of-interest (VOI)-based background and lesion analysis for visible tumour lesions with a
## Related Clinical Research

- [GLUT10 (SLC2A10) Expression in Breast Cancer and Its Role in Cisplatin Resistance](https://medichelpline.com/clinical-feed/pubmed-42595549.md) (DOI: 10.3760/cma.j.cn112152-20251018-00521)
- [Choroidal metastasis: Age and metastatic burden predict survival in a single-center cohort](https://medichelpline.com/clinical-feed/plos-one-12-choroidal-metastasis-impact-of-primary-tumors-and-age-on-survival-a-single.md)
- [Challenging FDA-Approved Cancer Drug Dosages: A Patient and Research Perspective](https://medichelpline.com/clinical-feed/kff-health-news-2-how-much-of-a-cancer-drug-is-too-much-patients-researchers-challenge-fda.md)
- [Predicting Cancer Immunotherapy Response Using Dynamic CD8+ T Cell Changes — Pan‑Cancer Retrospect](https://medichelpline.com/clinical-feed/frontiers-in-immunology-13-a-predictive-model-for-immunotherapy-efficacy-in-cancer-based-on-dynamic.md)
- [CT-guided intratumoral immunotherapy for advanced solid tumors: safety and systemic effects](https://medichelpline.com/clinical-feed/frontiers-in-immunology-3-ct-guided-intratumoral-immunotherapy-for-advanced-solid-tumors-a-prospective.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.